QL1706
Phase 3Small molecule
Qilu Pharmaceutical Co., Ltd.QL1706 is one of 580 small molecule programs targeting Pancreatic Cancer. It is currently in Phase 3.
29
Indications
51
Total Trials
41
Active Trials
579
Competitors
Pipeline
Status by Indication[3][1]
Indication
Showing 10 of 29 indications
Competition
Competitive Landscape
744 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1QL1706
Qilu Pharmaceutical Co., Ltd.Phase 3
Lexiscan
AstellasPreclinical
Voltaren
NovartisPreclinical
Blenoxane
Bristol-Myers SquibbPreclinical
Duragesic-100
CCephalon
Preclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Duragesic
CCephalon
Preclinical
Sporanox
SSebela Pharmaceuticals Development LLC
Preclinical
Tricor
JJagotec
Preclinical
Cortef
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Cervical Cancer5 trials
Show 2 more trials
QL1706 in Patients With Recurrent and Metastatic Cervical Cancer Resistant to Prior PD-1/PD-L1 Antibody Therapy
Not yet recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT07141186·50 enrolled
Hepatocellular Carcinoma5 trials
Breast Cancer5 trials
Evaluation of Neoadjuvant Therapy With Trastuzumab, Pertuzumab, Docetaxel, and QL1706 in Early or Locally Advanced HER2+ Breast Cancer
Not yet recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT07246317·188 enrolled
Non-Small Cell Lung Cancer3 trials
Small Cell Lung Cancer2 trials
28 more indications
First-line Treatment2 trials
Nasopharyngeal Carcinoma2 trials
Pancreatic Cancer2 trials
QL1706 Plus Chidamide, AG as First-line Treatment for Metastatic Pancreatic Cancer
Recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT06951997·33 enrolled
Metastatic Colorectal Cancer1 trial
Advanced Malignant Solid Tumors1 trial
Stage III Colon Cancer1 trial
Esophageal Carcinoma1 trial
Efficacy and Safety of QL1706 Plus Lenvatinib As 2nd Line Theapy in Patients with Metastatic Esophageal Carcinoma After Disease Progression on ICIs Therapy
Not yet recruiting·TThe First Affiliated Hospital of Zhengzhou University·Phase 1/2·NCT06746961·49 enrolled
Liver Metastases1 trial
Colon Cancer1 trial
Second-line Treatment1 trial
Patients With Advanced Solid Tumors1 trial
Ovarian Clear Cell Carcinoma1 trial
Non-squamous NSCLC1 trial
Patients With Solid Tumors1 trial
Gastric Cancer1 trial
QL1706-SOX vs SOX Alone as Neoadjuvant Therapy for Resectable Diffuse-Type Gastric Cancer
Not yet recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT07315035·74 enrolled
Intrahepatic Cholangiocarcinoma1 trial
Treatment1 trial
Resectable NSCLC1 trial
Perioperative Study of Iparomlimab and Tuvonralimab in Resectable NSCLC
Recruiting·—·Phase 2·NCT06897046·90 enrolled
Phase II1 trial
A Phase II Study of CRT Combined With QL1706 in ESCC Patients
Recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT05490719·39 enrolled
Ovarian Cancer1 trial
Leptomeningeal Metastasis1 trial
Biliary Tract Tumors1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for QL1706. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details